In the CAR-T field, we can perform comprehensive data retrieval of CAR-T in two major parts: antibody search and CAR expression cassette design.

Benitec Biopharma has reported initial dosing in an early-stage trial for its genetic treatment prospect, BB-301, aimed at tackling Oculopharyngeal Muscular Dystrophy.

Nrf2 inhibitors are compounds that target the Nrf2 transcription factor, crucial for defense against oxidative stress.

Ambrx Reports Progress on APEX-01 Trial, a Phase 1 / 2 Study Assessing Increasing Doses of ARX517, Its Own PSMA-Directed Antibody-Drug Conjugate, in Advanced Prostate Cancer Unresponsive to Hormonal Therapy.

Myostatin inhibitors are drugs that target myostatin, a protein that regulates muscle growth. The future of myostatin inhibitors is promising, with potential applications in treating muscle-wasting conditions.

uniQure N.V., a leader in gene therapy, has announced FDA approval of its IND application for AMT-191 to treat severe medical conditions.

mTOR inhibitors are drugs that target the mTOR protein kinase, crucial for regulating cell growth and survival.

BioVie Inc., a biopharmaceutical firm focusing on neurological, neurodegenerative, and severe liver diseases, reported positive initial results from its Phase 3 trial of NE3107 in mild to moderate Alzheimer’s patients.

Somatic cell gene therapy targets those cells of the body that are not involved in reproduction – the somatic cells.

Carisma Therapeutics Inc. has confirmed that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for their novel product, CT-0525.

MDM2 inhibitors are drugs that target the MDM2 protein, crucial for regulating the tumor suppressor protein p53.

Bio-Thera Solutions has reported encouraging outcomes from its pivotal Phase 3 clinical trial involving BAT2206, a candidate biosimilar for Stelara®.